CorrespondenceFatal MDMA intoxication
References (5)
- et al.
Fatal interaction between ritonavir and MDMA
Lancet
(1998) - et al.
The demethylenation of methylenedioxyamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)
Biochem Pharmacol
(1994)
Cited by (42)
Severe or life-threatening interactions between antiretrovirals and non-HIV drugs
2015, Enfermedades Infecciosas y Microbiologia Clinica MonografiasDrugs of Abuse
2008, Pediatric Emergency MedicineCYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA)
2007, ToxicologyCitation Excerpt :It would be of great interest to investigate whether the UM phenotype (up to 5% of the Caucasians) characterized by multiple CYP2D6 gene copies is over represented in the cases of 4-MTA and other amphetamine designer drug-related intoxications. According to our results this may be more relevant than the genotyping of the most common deficient alleles that has already been performed in previous studies (Gilhooly and Daly, 2002; O’Donohoe et al., 1998; Schwab et al., 1999). Recently, we have shown that toxicity of 3,4-methylenedioxymethamphetamine (MDMA) was clearly increased in cells expressing CYP2D6*1 compared to the parental cells devoid of CYP-dependent enzymatic activity (Carmo et al., 2006).
Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?
2007, Neuroscience and Biobehavioral ReviewsAcute and long term effects of ecstasy
2004, Presse MedicaleAltered states: The clinical effects of Ecstasy
2003, Pharmacology and TherapeuticsCitation Excerpt :Therefore, cerebrovascular and cardiovascular complications may be a direct effect of MDMA ingestion. Ecstasy ingestion can cause hepatotoxicity, and there are different patterns of hepatotoxicity, which suggest that there may be different mechanisms of pathogenesis (Andreu et al., 1998; Brauer et al., 1997; Coore, 1996; Dykhuizen et al., 1995; Ellis et al., 1996; Gorard et al., 1992; Hellinger et al., 1997; Henry et al., 1992; Jones & Simpson, 1999; Milroy et al., 1996; Schwab et al., 1999; Shearman et al., 1992). In one Spanish intensive care unit between 1994 and 1996, Ecstasy was the second most common cause of acute liver failure for the under 25s (Andreu et al., 1998).